-
1 Comment
Uscom Limited is currently in a long term uptrend where the price is trading 1.5% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Uscom Limited's total revenue rose by 188.5% to $3M since the same quarter in the previous year.
Its net income has increased by 82.0% to $-270K since the same quarter in the previous year.
Finally, its free cash flow grew by 149.5% to $194K since the same quarter in the previous year.
Based on the above factors, Uscom Limited gets an overall score of 5/5.
ISIN | AU000000UCM2 |
---|---|
Sector | Healthcare |
Industry | Medical Devices |
Exchange | AU |
CurrencyCode | AUD |
PE Ratio | None |
---|---|
Target Price | 0.3 |
Market Cap | 6M |
Beta | -1.28 |
Dividend Yield | None |
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and other medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for UCM.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025